drugset / Trial / NCT00367770
BREATHE 5-OL: Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This 6-month open label study will evaluate the long term safety of bosentan (via oxygen saturation) and efficacy (exercise capacity) in patients who have completed the BREATHE-5 study (PAH related to Eisenmenger physiology). Treatment duration is 6 months.
Timeline
- Start
- 2004-01
- Primary completion
- 2005-12
- Completion
- 2005-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bosentan | Other / unclassified | 62.5 mg | — |
| Subject | Bosentan | Other / unclassified | 125 mg | — |